Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Budesonide for Rhinitis During High Pollution
NCT04132570Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of EPI-EE in rhinitis (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Change from Baseline in 24-hour Reflective Total Nasal Symptom Score at 10 days. Started Oct 2019; status: completed.
02
Drugs
EPI-EE
03
Conditions
rhinitis
Beyond the preview
Go deeper on NCT04132570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132570.